MEDICAL DEVICES & INNOVATIONS
Abbott wins FDA approval of Eterna spinal cord stimulation system
USA – Abbott Laboratories has received FDA approval for its Eterna spinal cord stimulation (SCS) system for chronic pain management. The Eterna SCS system is the smallest implantable, rechargeable system currently available for this indication on the market. Abbott claims that it was created after extensive research with patients, physicians, and caregivers to better understand the unmet needs of chronic pain patients. SCS technology reduces pain by
23% more than traditional waveform technology approaches. It improves the patient charging experience by requiring as few as five recharges per year when used in conjunction with a wireless charger. To provide superior pain relief, Eterna SCS employs the company’s proprietary low-dose BurstDR stimulation, which mimics natural firing patterns in the brain. Eterna also employs Abbott’s TotalScan MRI technology, which allows for fullbody MRI scans — a critical need for chronic pain patients who require access to advanced diagnostics and healthcare. The system is anticipated to provide laboratories performing highly sensitive and precise DNA and RNA analysis with flexibility through three unique reaction plates. In addition, the regulatory decision is expected to strengthen Abbott’s Established Pharmaceuticals Division (EPD).
Thermo Fisher Scientific introduces all-in-one AAV production system USA — Thermo Fisher Scientific has introduced the Gibco CTS AAV-MAX Helper-Free AAV Production System, a new all-in-one solution designed to help meet clinical and commercial demands for cost-effective and scalable development of adeno-associated virus (AAV)-based gene therapies. As part of Cell Therapy Systems (CTS) solutions, the CTS AAV-MAX System is designed to work within the AAV production workflow, from cell culture and transfection through AAV viral vector production.
BD launches third-generation total lab automation system for microbiology labs USA – Becton, Dickinson and Company (BD) has launched the new third-generation BD Kiestra Total Lab Automation (TLA) System for microbiology laboratories. BD Kiestra lab solutions, including scalable and modular microbiology workflow automation solutions, offer total lab automation for the clinical microbiology laboratory. Currently, two companies offer distinct TLA solutions in microbiology: BD-Kiestra and bioMérieux & Copan (WASPLab). The robotic track system is suitable for use with the BD Kiestra microbiology laboratory solution, which automates lab specimen processing. Designed to meet the evolving requirements of labs, the new robotic track system will enable the formation of a custom and flexible total lab automation configuration that can HEALTHCAREAFRICA.INFO
link several BD Kiestra modules. The workflow can be completely automated, from routine specimen inoculation processes to advanced incubation, imaging, and colony selection for the detection of pathogens. Using BD Synapsys informatics solution, each step of the lab’s diagnostic pathway can be traced. The solution will help improve laboratory decisionmaking and productivity through integrated workflows and on-demand insights.
It is currently the only product of its kind manufactured under cGMP conditions, allowing for large-scale applications. The system can save manufacturers up to 50% on production costs when compared to alternative polyethyleneimine (PEI)-based suspension systems, and it can help reduce plasmid DNA costs by 25%. It also features a mammalian-based suspension system comprised of a clonal HEK293 cell line and animal originfree reagents that support scalable AAV production from shake flask to bioreactor scale. In addition, the CTS AAV-MAX System allows researchers to seamlessly transition from research on the Gibco AAV-MAX Helper Free AAV Production System to clinical scale.
JAN/FEB 2023 | HEALTHCARE MIDDLE EAST & AFRICA
71